Trials / Completed
CompletedNCT00457561
Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- Hamamatsu University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.
Conditions
Timeline
- First posted
- 2007-04-06
- Last updated
- 2007-04-06
Source: ClinicalTrials.gov record NCT00457561. Inclusion in this directory is not an endorsement.